哌拉西林/他唑巴坦治疗住院患者泌尿系统感染的疗效分析

Efficacy of piperacillin-tazobactam in treatment of urinary tract infections of hospitalized patients

目的观察哌拉西林/他唑巴坦治疗住院患者泌尿系统感染临床疗效,分析其有效性和安全性。方法将94例患者随机分为试验组和对照组,试验组用哌拉西林/他唑巴坦,对照组用替卡西林/克拉维酸治疗,比较两组在疗效和细菌清除效果的变化。结果试验组与对照组可进行疗效评价各47例,可进行安全性评价各47例;试验组痊愈28例,显效19例,总有效率100.00%,对照组痊愈22例,显效17例,进步8例,总有效率82.98%,两组比较差异有统计学意义(P<0.05);细菌清除率试验组为100.00%,对照组为82.98%,两组比较差异有统计学意义(P<0.05);试验组无不良反应发生,对照组有2例患者出现不良反应,不良反应发生为4.25%,两组差异有统计学意义(P<0.05)。结论哌拉西林/他唑巴坦治疗泌尿系统感染的临床疗效明显,细菌清除率高,安全可靠,值得临床推广应用。

OBJECTIVE To observe the clinical efficacy of piperacillin-tazobactam in the treatment of hospitalized patients with urinary tract infections and analyze the effectiveness and safety. METHODS A total of 94 patients were randomly divided into the experimental group and the control group, the experimental group was treated with the piperacillin-tazobactam, while the control group was treated with ticarcillin/clavulanic acid, the efficacy and the bacterial clearance effects were compared between the two groups. RESULTS There were 47 cases in each of the experimental group and the control group that were qualified for the evaluation of efficacy and 47 cases in each group qualified for the evaluation of safety. In the experimental group, there were 28 cases cured and 19 cases effective with the total effective rate of 100. 00% in the control group, there were 22 cases cured, 17 cases effective, and 8 cases improved with the total effective rate of 82.98%, the difference between the experimental group and the control group was statistically significant（P〈0.05）. The bacterial clearance rate of the experimen- tal group was 100.00%, the control group 82.98%, the difference between the two groups was statistically sig- nificant （P〈0.05）. Among the 47 cases of patients in the experimental group, there were no cases with adverse reaction, and there were 2 cases of adverse reactions in the control group with the incidence rate of 4.25M, the difference between the two groups was statistically significant （P〈0.05）. CONCLUSION Piperacillih-tazobactam can achieve significant clinical efficacy in the treatment of urinary tract infections, with the bacterial clearance rate high, the safety reliable, which is worthy of the clinical promotion.